Robert Jr. Baltera Purchases 20,000 Shares of Palisade Bio (NASDAQ:PALI) Stock

Palisade Bio, Inc. (NASDAQ:PALI) Director Robert Jr. Baltera bought 20,000 shares of Palisade Bio stock in a transaction dated Monday, July 6th. The shares were bought at an average cost of $2.05 per share, with a total value of $41,000.00. Following the completion of the transaction, the director directly owned 386,904 shares in the company, valued at approximately $793,153.20. This trade represents a 5.45% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.

Robert Jr. Baltera also recently made the following trade(s):

• On Tuesday, July 7th, Robert Jr. Baltera bought 30,000 shares of Palisade Bio stock. The shares were acquired at an average price of $2.03 per share, with a total value of $60,900.00.
• On Thursday, July 2nd, Robert Jr. Baltera bought 10,000 shares of Palisade Bio stock. The shares were bought at an average price of $1.98 per share, for a total transaction of $19,800.00.
• On Wednesday, July 1st, Robert Jr. Baltera purchased 20,000 shares of Palisade Bio stock. The shares were bought at an average price of $1.98 per share, for a total transaction of $39,600.00.

Palisade Bio Price Performance

NASDAQ PALI opened at $1.97 on Friday. The company’s 50 day simple moving average is $1.92 and its two-hundred day simple moving average is $1.92. The stock has a market capitalization of $341.95 million, a PE ratio of -1.95 and a beta of 1.50. Palisade Bio, Inc. has a 1 year low of $0.53 and a 1 year high of $2.86.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). On average, research analysts anticipate that Palisade Bio, Inc. will post -0.25 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on PALI. HC Wainwright reaffirmed a “buy” rating and set a $2.00 price objective on shares of Palisade Bio in a research note on Tuesday, June 30th. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Oppenheimer set a $7.00 price objective on shares of Palisade Bio in a research report on Tuesday, June 30th. Weiss Ratings raised shares of Palisade Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 29th. Finally, Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Sunday, July 5th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $8.83.

Institutional Investors Weigh In On Palisade Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Commodore Capital LP purchased a new position in shares of Palisade Bio during the fourth quarter valued at approximately $26,896,000. Perceptive Advisors LLC purchased a new position in Palisade Bio during the fourth quarter valued at $28,318,000. BIT Capital GmbH bought a new stake in Palisade Bio in the fourth quarter worth $717,000. Creek Drive Management Group LLC purchased a new stake in shares of Palisade Bio in the fourth quarter worth $723,000. Finally, Artia Global Partners LP bought a new position in shares of Palisade Bio during the fourth quarter valued at $4,682,000. Hedge funds and other institutional investors own 11.79% of the company’s stock.

About Palisade Bio

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.